ME‐401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3‐KINASE P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B‐CELL LYMPHOID MALIGNANCIES. (June 2017) - Ghalie, R.G.; Pagel, J.M.; Soumerai, J.; Iasonos, A.; Patel, K.; Moreno, O.; Butler, T.; Zelenetz, A.D.